Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent

Next Previous
Trial Profile

A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bintrafusp alfa (Primary)
  • Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Urethral cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 12 Apr 2024 Status changed from active, no longer recruiting to discontinued, as primary investigator withdrew the participant due to an SAE.
  • 24 Oct 2023 Results (Between Oct 15, 2020, and Aug 31, 2021) assessing the safety and efficacy of bintrafusp alfa in platinum-based chemotherapy-refractory in locally advanced unresectable or metastatic urothelial cancer, presented at the 48th European Society for Medical Oncology Congress.
  • 22 Sep 2022 Planned primary completion date changed from 2 Aug 2022 to 2 Nov 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top